Brandon Aden1, Allison Dunning, Bohdan Nosyk, Eve Wittenberg, Jeremy W Bray, Bruce R Schackman. 1. Departments of *Medicine; †Healthcare Policy and Research, Weill Cornell Medical College, New York, NY; ‡British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; §Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada; ‖Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA; and ¶Department of Economics, The University of North Carolina at Greensboro, Greensboro, NC.
Abstract
OBJECTIVE: To assess the impact of illicit drug use on health-related quality of life (health utility) among opioid-dependent HIV-infected patients. DESIGN: Secondary analyses of data from the Buprenorphine-HIV Evaluation and Support cohort of HIV-infected patients with opioid dependence in 9 US HIV clinics between 2004 and 2009. Health status [short form-12 (SF-12)], combination antiretroviral treatment (ART) status, CD4 cell count, hepatitis C virus antibody status, current drug use, and demographics were assessed at the initial visit and quarterly follow-up visits until 1 year. The SF-6D health utility scores were derived from the SF-12. Multivariate mixed-effects regression models were used to assess the impact of illicit drug use on health utility controlling for demographic, clinical, and social characteristics. RESULTS: Health utility was assessed among 307 participants, 67% male, with a median age of 46 years at 1089 quarterly assessments. In multivariate analyses, illicit opioid use, nonopioid illicit drug use, not being on ART, and being on ART with poor adherence were associated with lower health utility. The observed decrement in health utility associated with illicit opioid use was larger for those on ART with good adherence (beta = -0.067; P < 0.01) or poor adherence (-0.049; P < 0.01) than for those not on ART. CONCLUSIONS: Illicit opioid and nonopioid drug use are negatively associated with health utility in patients with HIV; however, the relative effect of illicit opioid use is smaller than that of not being on ART. Postponing ART until initiation of opioid substitution therapy or abstinence may have limited benefits from the perspective of maximizing health utility.
OBJECTIVE: To assess the impact of illicit drug use on health-related quality of life (health utility) among opioid-dependent HIV-infectedpatients. DESIGN: Secondary analyses of data from the Buprenorphine-HIV Evaluation and Support cohort of HIV-infectedpatients with opioid dependence in 9 US HIV clinics between 2004 and 2009. Health status [short form-12 (SF-12)], combination antiretroviral treatment (ART) status, CD4 cell count, hepatitis C virus antibody status, current drug use, and demographics were assessed at the initial visit and quarterly follow-up visits until 1 year. The SF-6D health utility scores were derived from the SF-12. Multivariate mixed-effects regression models were used to assess the impact of illicit drug use on health utility controlling for demographic, clinical, and social characteristics. RESULTS: Health utility was assessed among 307 participants, 67% male, with a median age of 46 years at 1089 quarterly assessments. In multivariate analyses, illicit opioid use, nonopioid illicit drug use, not being on ART, and being on ART with poor adherence were associated with lower health utility. The observed decrement in health utility associated with illicit opioid use was larger for those on ART with good adherence (beta = -0.067; P < 0.01) or poor adherence (-0.049; P < 0.01) than for those not on ART. CONCLUSIONS: Illicit opioid and nonopioid drug use are negatively associated with health utility in patients with HIV; however, the relative effect of illicit opioid use is smaller than that of not being on ART. Postponing ART until initiation of opioid substitution therapy or abstinence may have limited benefits from the perspective of maximizing health utility.
Authors: Don Husereau; Michael Drummond; Stavros Petrou; Chris Carswell; David Moher; Dan Greenberg; Federico Augustovski; Andrew H Briggs; Josephine Mauskopf; Elizabeth Loder Journal: Value Health Date: 2013 Mar-Apr Impact factor: 5.725
Authors: Bohdan Nosyk; Huiyung Sun; Daphne P Guh; Eugenia Oviedo-Joekes; David C Marsh; Suzanne Brissette; Martin T Schechter; Aslam H Anis Journal: J Clin Epidemiol Date: 2010-03-17 Impact factor: 6.437
Authors: David A Fiellin; Linda Weiss; Michael Botsko; James E Egan; Frederick L Altice; Lauri B Bazerman; Amina Chaudhry; Chinazo O Cunningham; Marc N Gourevitch; Paula J Lum; Lynn E Sullivan; Richard S Schottenfeld; Patrick G O'Connor Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Bruce R Schackman; Sue J Goldie; Kenneth A Freedberg; Elena Losina; John Brazier; Milton C Weinstein Journal: Med Decis Making Date: 2002 Jan-Feb Impact factor: 2.583
Authors: Dennis G Fryback; Nancy Cross Dunham; Mari Palta; Janel Hanmer; Jennifer Buechner; Dasha Cherepanov; Shani A Herrington; Ron D Hays; Robert M Kaplan; Theodore G Ganiats; David Feeny; Paul Kind Journal: Med Care Date: 2007-12 Impact factor: 2.983
Authors: Eve Wittenberg; Jeremy W Bray; Brandon Aden; Achamyeleh Gebremariam; Bohdan Nosyk; Bruce R Schackman Journal: Addiction Date: 2015-12-17 Impact factor: 6.526
Authors: Ali Jalali; Danielle A Ryan; Philip J Jeng; Kathryn E McCollister; Jared A Leff; Joshua D Lee; Edward V Nunes; Patricia Novo; John Rotrosen; Bruce R Schackman; Sean M Murphy Journal: Drug Alcohol Depend Date: 2020-08-05 Impact factor: 4.492
Authors: Michael J Silverberg; Derek D Satre; J Carlo Hojilla; Edda I Santiago-Rodriguez; Stacy Sterling; Emily C Williams; Wendy Leyden; C Bradley Hare Journal: AIDS Behav Date: 2021-01